Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Measles Maternal Antibodies With Low Avidity Do Not Interfere With the Establishment of Robust Quantity and Quality Antibody Responses After the Primary Dose of Measles, Mumps, and Rubella Vaccine Administered at 12-Months of Age.

Collins CA, Gelinas L, Yasukawa LL, Audet S, Abu-Raya B, Turvey SE, Beeler JA, Kollmann TR, Gans HA.

J Pediatric Infect Dis Soc. 2019 Oct 23. pii: piz074. doi: 10.1093/jpids/piz074. [Epub ahead of print]

PMID:
31644795
2.

Development of a high-throughput assay to measure measles neutralizing antibodies.

Alvarado-Facundo E, Audet S, Moss WJ, Beeler JA.

PLoS One. 2019 Aug 15;14(8):e0220780. doi: 10.1371/journal.pone.0220780. eCollection 2019. Erratum in: PLoS One. 2019 Sep 23;14(9):e0223156.

3.

Development of Luciferase Immunoprecipitation Systems (LIPS) Assay to Detect IgG Antibodies against Human Respiratory Syncytial Virus G-Glycoprotein.

Crim RL, Kumari S, Jayanti P, Audet S, Kulkarni A, Beeler J.

Vaccines (Basel). 2019 Feb 1;7(1). pii: E16. doi: 10.3390/vaccines7010016.

4.

Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.

Lemieux J, Audet S.

Curr Oncol. 2018 Jun;25(Suppl 1):S161-S170. doi: 10.3747/co.25.3846. Epub 2018 Jun 13.

5.

Life after PACE (Program of All-Inclusive Care for the Elderly): A retrospective/prospective, qualitative analysis of the impact of closing a nurse practitioner centered PACE site.

Meunier MJ, Brant JM, Audet S, Dickerson D, Gransbery K, Ciemins EL.

J Am Assoc Nurse Pract. 2016 Nov;28(11):596-603. doi: 10.1002/2327-6924.12379. Epub 2016 May 27.

PMID:
27232590
6.

Supplemental measles vaccine antibody response among HIV-infected and -uninfected children in Malawi after 1- and 2-dose primary measles vaccination schedules.

Fowlkes AL, Witte D, Beeler J, Audet SA, Broadhead R, Bellini WJ, Cutts F, Helfand RF.

Vaccine. 2016 Mar 14;34(12):1459-64. doi: 10.1016/j.vaccine.2016.01.055. Epub 2016 Feb 9.

7.

Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.

Fiebelkorn AP, Coleman LA, Belongia EA, Freeman SK, York D, Bi D, Kulkarni A, Audet S, Mercader S, McGrew M, Hickman CJ, Bellini WJ, Shivakoti R, Griffin DE, Beeler J.

J Infect Dis. 2016 Apr 1;213(7):1115-23. doi: 10.1093/infdis/jiv555. Epub 2015 Nov 23.

8.

Development of a luciferase immunoprecipitation system assay to detect IgG antibodies against human respiratory syncytial virus nucleoprotein.

Kumari S, Crim RL, Kulkarni A, Audet SA, Mdluli T, Murata H, Beeler JA.

Clin Vaccine Immunol. 2014 Mar;21(3):383-90. doi: 10.1128/CVI.00594-13. Epub 2014 Jan 8.

9.

A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment.

Varada JC, Teferedegne B, Crim RL, Mdluli T, Audet S, Peden K, Beeler J, Murata H.

Virol J. 2013 Jun 15;10:195. doi: 10.1186/1743-422X-10-195.

10.

Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age.

Gans HA, Yasukawa LL, Sung P, Sullivan B, DeHovitz R, Audet S, Beeler J, Arvin AM.

J Infect Dis. 2013 Feb 15;207(4):574-82. doi: 10.1093/infdis/jis719. Epub 2013 Jan 8.

11.

Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy.

Abzug MJ, Qin M, Levin MJ, Fenton T, Beeler JA, Bellini WJ, Audet S, Sowers SB, Borkowsky W, Nachman SA, Pelton SI, Rosenblatt HM; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams.

J Infect Dis. 2012 Aug 15;206(4):512-22. doi: 10.1093/infdis/jis386. Epub 2012 Jun 12.

12.

Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously.

Wong-Chew RM, García-León ML, Espinosa-Torres Torrija B, Hernández-Pérez B, Cardiel-Marmolejo LE, Beeler JA, Audet S, Santos-Preciado JI.

J Infect Dis. 2011 Aug 1;204(3):426-32. doi: 10.1093/infdis/jir278.

13.

Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225.

Chandwani S, Beeler J, Li H, Audet S, Smith B, Moye J, Nalin D, Krasinski K; PACTG 225 Study Team.

J Infect Dis. 2011 Jul;204 Suppl 1:S179-89. doi: 10.1093/infdis/jir089.

14.

Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated individuals.

Hickman CJ, Hyde TB, Sowers SB, Mercader S, McGrew M, Williams NJ, Beeler JA, Audet S, Kiehl B, Nandy R, Tamin A, Bellini WJ.

J Infect Dis. 2011 Jul;204 Suppl 1:S549-58. doi: 10.1093/infdis/jir106.

PMID:
21666212
15.

Persistence of vaccine-induced measles antibody beyond age 12 months: a comparison of response to one and two doses of Edmonston-Zagreb measles vaccine among HIV-infected and uninfected children in Malawi.

Fowlkes A, Witte D, Beeler J, Audet S, Garcia P, Curns A, Yang C, Fudzulani R, Broadhead R, Bellini WJ, Cutts F, Helfand RF.

J Infect Dis. 2011 Jul;204 Suppl 1:S149-57. doi: 10.1093/infdis/jir135.

PMID:
21666156
16.

ELISA underestimates measles antibody seroprevalence in US military recruits.

Mancuso JD, Krauss MR, Audet S, Beeler JA.

Vaccine. 2008 Sep 8;26(38):4877-8. doi: 10.1016/j.vaccine.2008.06.028. Epub 2008 Jun 27.

PMID:
18586062
17.

Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak.

Rubin SA, Qi L, Audet SA, Sullivan B, Carbone KM, Bellini WJ, Rota PA, Sirota L, Beeler J.

J Infect Dis. 2008 Aug 15;198(4):508-15. doi: 10.1086/590115.

PMID:
18558869
18.

Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination.

Cohen BJ, Audet S, Andrews N, Beeler J; WHO working group on measles plaque reduction neutralization test.

Vaccine. 2007 Dec 21;26(1):59-66. Epub 2007 Nov 12.

PMID:
18063236
19.

The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants.

Scott S, Moss WJ, Cousens S, Beeler JA, Audet SA, Mugala N, Quinn TC, Griffin DE, Cutts FT.

Clin Infect Dis. 2007 Dec 1;45(11):1417-24. Epub 2007 Oct 22.

PMID:
17990222
20.

Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study.

Moss WJ, Scott S, Mugala N, Ndhlovu Z, Beeler JA, Audet SA, Ngala M, Mwangala S, Nkonga-Mwangilwa C, Ryon JJ, Monze M, Kasolo F, Quinn TC, Cousens S, Griffin DE, Cutts FT.

J Infect Dis. 2007 Aug 1;196(3):347-55. Epub 2007 Jun 19.

PMID:
17597448
21.

Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment.

LeBaron CW, Beeler J, Sullivan BJ, Forghani B, Bi D, Beck C, Audet S, Gargiullo P.

Arch Pediatr Adolesc Med. 2007 Mar;161(3):294-301.

PMID:
17339511
22.

Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants.

D'Angio CT, Boohene PA, Mowrer A, Audet S, Menegus MA, Schmid DS, Beeler JA.

Pediatrics. 2007 Mar;119(3):e574-9.

PMID:
17332177
23.

Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity.

Crim RL, Audet SA, Feldman SA, Mostowski HS, Beeler JA.

J Virol. 2007 Jan;81(1):261-71. Epub 2006 Oct 18.

24.

Measles-virus-neutralizing antibodies in intravenous immunoglobulins.

Audet S, Virata-Theimer ML, Beeler JA, Scott DE, Frazier DJ, Mikolajczyk MG, Eller N, Chen FM, Yu MY.

J Infect Dis. 2006 Sep 15;194(6):781-9. Epub 2006 Aug 16.

PMID:
16941344
25.

Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children.

Wong-Chew RM, Islas-Romero R, García-García Mde L, Beeler JA, Audet S, Santos-Preciado JI, Gans H, Lew-Yasukawa L, Maldonado YA, Arvin AM, Valdespino-Gómez JL.

Vaccine. 2006 Jan 30;24(5):683-90. Epub 2005 Aug 24.

PMID:
16154241
26.
27.

Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.

Gans HA, Yasukawa LL, Alderson A, Rinki M, DeHovitz R, Beeler J, Audet S, Maldonado Y, Arvin AM.

J Infect Dis. 2004 Jul 1;190(1):83-90. Epub 2004 May 26.

PMID:
15195246
28.

Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children.

Wong-Chew RM, Islas-Romero R, García-García Mde L, Beeler JA, Audet S, Santos-Preciado JI, Gans H, Lew-Yasukawa L, Maldonado YA, Arvin AM, Valdespino-Gómez JL.

J Infect Dis. 2004 Jan 15;189(2):254-7. Epub 2004 Jan 5.

PMID:
14722890
29.

Cellular and humoral immune responses to measles in immune adults re-immunized with measles vaccine.

Wong-Chew RM, Beeler JA, Audet S, Santos JI.

J Med Virol. 2003 Jun;70(2):276-80.

PMID:
12696117
30.

Human respiratory syncytial virus surface glycoproteins F, G and SH form an oligomeric complex.

Feldman SA, Crim RL, Audet SA, Beeler JA.

Arch Virol. 2001 Dec;146(12):2369-83.

PMID:
11811686
31.

Evaluation of an early two-dose measles vaccination schedule.

Hutchins SS, Dezayas A, Le Blond K, Heath J, Bellini W, Audet S, Beeler J, Wattigney W, Markowitz L.

Am J Epidemiol. 2001 Dec 1;154(11):1064-71.

PMID:
11724724
32.

Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months.

Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, Beeler J, Audet S, Maldonado Y, Arvin AM.

J Infect Dis. 2001 Oct 1;184(7):817-26. Epub 2001 Aug 22.

PMID:
11528592
34.

Evaluation of vaccines, interferons and cell substrates for pestivirus contamination.

Audet SA, Crim RL, Beeler J.

Biologicals. 2000 Mar;28(1):41-6.

PMID:
10799055
35.

Divergence of binding, signaling, and biological responses to recombinant human hybrid IFN.

Hu R, Bekisz J, Hayes M, Audet S, Beeler J, Petricoin E, Zoon K.

J Immunol. 1999 Jul 15;163(2):854-60.

36.

IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants.

Gans HA, Maldonado Y, Yasukawa LL, Beeler J, Audet S, Rinki MM, DeHovitz R, Arvin AM.

J Immunol. 1999 May 1;162(9):5569-75.

37.

Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-alpha.

Grimley PM, Fang H, Rui H, Petricoin EF 3rd, Ray S, Dong F, Fields KH, Hu R, Zoon KC, Audet S, Beeler J.

Blood. 1998 Apr 15;91(8):3017-27.

PMID:
9531615
38.

Antiproliferative action of interferon-alpha requires components of T-cell-receptor signalling.

Petricoin EF 3rd, Ito S, Williams BL, Audet S, Stancato LF, Gamero A, Clouse K, Grimley P, Weiss A, Beeler J, Finbloom DS, Shores EW, Abraham R, Larner AC.

Nature. 1997 Dec 11;390(6660):629-32.

PMID:
9403695
39.

Reduced seroconversion to measles in infants given vitamin A with measles vaccination.

Semba RD, Munasir Z, Beeler J, Akib A, Muhilal, Audet S, Sommer A.

Lancet. 1995 May 27;345(8961):1330-2.

PMID:
7752754

Supplemental Content

Support Center